Saturday, May 28, 2011 11:54:31 AM
Dr. Philip E. Thorpe, UTSW-MC ( http://www.utsouthwestern.edu/findfac/research/0,2357,17308,00.html )
5-26-11, Informa’s Recombinant Antibodies Conf. (Barcelona)
“Targeting Tumor Vasculature & Reactivating Tumor Immunity with Bavituximab: Preclin. & Clinical Studies”
PDF: http://peregrineinc.com/images/stories/pdfs/thorpe_peregrine_bavituximab_keynote.pdf (53 slides)
5-26-11 Press Release: http://tinyurl.com/3klpodc
“Keynote Presentation at Leading European Antibody Conference Highlights Immune Reactivation Mechanisms of Bavituximab”
Slide 41:
COMMENTARY ON SLIDE 41 BY IHUB’S “FIRE FOX”, 5-27-11 #64371
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=63661054
“RRDog-- Your Ode to Dr. Thorpe is well sung. I agree completely. The market doesn't appreciate the MOA "tour de force" Thorpe has pulled off here. However, for the FDA, the analysts and the medical community considering Bavi trials, Thorpe's presentation in Barcelona will be hugely compelling for years to come. I bet many aspiring PhD candidates are already making plans to replicate new versions of this break-through Phil Thorpe accomplishment. An immunology maven I spoke with emphasized the importance of Slide #41, which tells the whole story in one picture. Everyone who owns stock in PPHM should print Slide 41 and keep it by their bedside. If Bavi indeed triggers either of these MOA mechanisms, it's the launch of huge new therapeutic platform - certainly in cancer and perhaps in viral therapy as well. But if both of these mechanisms of action are operating, the effects of Bavi as an immunotherapy will be nothing short of sensational. The fact that Thorpe has nailed down these TWO separate ways that Bavi "breaks the grip of tumor on the immune system", indicates huge promise for Bavi !!!”
Slide 52:
DR. THORPE’S COMMENTS ON BAVI’S MOA FROM THE 5-26-11 PR:
"Our research shows that exposed PS in the tumor environment plays a fundamental immunosuppressive role that prevents the immune system from recognizing cancer cells as 'foreign,' resulting in cancer patients not being able to reject their tumors," said Philip E. Thorpe, Ph.D., professor of pharmacology in the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center, scientific adviser to Peregrine and inventor of the company's PS-targeting antibody technology. "We show that highly immunosuppressive cells called myeloid-derived suppressor cells, or MDSCs, accumulate in tumors and fail to mature into functional immune cells. What is especially exciting is that administration of PS-targeting antibodies like bavituximab breaks the grip of the tumor on the immune system. In treated animals, we see the disappearance of MDSCs and the appearance of functional immune cells, especially macrophages. The entire tumor environment shifts from being immunosuppressive to being immune responsive. These results have important implications for cancer therapy."
http://tinyurl.com/3klpodc
= = = = = = = = = = = = = = = = = = = = = =
SPEAKER INTERVIEW of Dr. Thorpe on his 5-26-11 Keynote Talk:
http://www.informaglobalevents.com/event/antibodies1/freedownloads
=> http://www.informaglobalevents.com/event/antibodies1/download/?id=3203
Recent CDMO News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:37:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:36:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:35:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 12:56:02 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/08/2024 09:32:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:56:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:55:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:53:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:51:57 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 12/19/2023 09:05:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:34:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:33:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:32:11 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:31:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:30:26 AM
FEATURED Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market • Mar 18, 2024 8:51 AM
FEATURED Prospera Energy Inc. Announces a 508% increase in the 2023 Proven Developed Producing (PDP) Reserve Valuation • Mar 18, 2024 8:09 AM
HealthLynked Corp Announces Chris Hall as New Chief Technology Officer • HLYK • Mar 19, 2024 8:00 AM
Greenlite Ventures Enters into Strategic Alliance with Woodway USA • GRNL • Mar 15, 2024 4:00 PM
HealthLynked Welcomes David Rosal as New Chief Financial Officer • HLYK • Mar 13, 2024 8:00 AM
ECGI Holdings, Inc. Announces Continued Efforts in Financial Optimization • ECGI • Mar 13, 2024 8:00 AM